US4380831077 - Common Stock
HOMOLOGY MEDICINES INC
NASDAQ:FIXX (3/25/2024, 8:23:28 PM)
After market: 0.892 -0.04 (-4.57%)0.9347
+0.01 (+0.77%)
Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company is headquartered in Bedford, Massachusetts and currently employs 92 full-time employees. The company went IPO on 2018-03-28. The Company’s clinical programs include HMI-103, an investigational gene editing candidate in clinical development for the treatment of patients with phenylketonuria (PKU); HMI-203, an investigational gene therapy candidate in clinical development for the treatment of patients with mucopolysaccharidosis type II (MPS II), or Hunter syndrome; and HMI-102, an investigational gene therapy candidate in clinical development for the treatment of adult patients with PKU. Its lead GTx-mAb gene therapy candidate, HMI-104, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). Its platform is designed to utilize human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs), to precisely and efficiently deliver single administration genetic medicines in vivo through a nuclease-free gene editing modality and gene therapy platform.
HOMOLOGY MEDICINES INC
1 Patriots Park
Bedford MASSACHUSETTS 01730
P: 17813017277
CEO: Arthur O. Tzianabos
Employees: 92
Website: https://www.homologymedicines.com/
BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common...
FIXX stock results show that Homology Medicines beat analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Homology Medicines (NASDAQ:FIXX) just reported results for the fourth quarter o...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Homology Medicines receives notification from Nasdaq regarding minimum bid price deficiency.
Here you can normally see the latest stock twits on FIXX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: